The Latest Breaking News from Novo Nordisk

Danish pharmaceutical company Novo Nordisk has signed a deal with South Africa’s Aspen Pharmacare to produce human insulin specifically for diabetes patients in Africa where there is a dire need for the life-saving treatment

These three biotech stocks have massive growth opportunities on the horizon, and could add a huge boost to any portfolio. They play in some of the most in demand markets on the planet, and have track records of finding ways to introduce products into those markets to capture big profits.…

Novo Nordisk stock skidded Monday on reports an inspection turned up "objectionable conditions" at a diabetes and weight-loss drugs manufacturing plant.

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from recession

The Nasdaq fell below its 50-day line with the market rally facing a big test. Meta is flirting with a buy point.

Ozempic has not shown increased risk of suicidal ideation in trials, but some users say it harmed their mental health.

In February 2021, The Conversation reported on a trial for a new weight-loss drug, called semaglutide, that was being hailed in the media as a “gamechanger”. Gamechanger is a word used far too often by journalists to describe things that are, frankly, mundane. This time, though, the word seems apt.

The Danish pharma giant overtook French luxury conglomerate LVMH as the most valuable European company, which held the title since 2021.

Danish drugmaker Novo Nordisk is now Europe's largest company in market capitalisation, ahead of French luxury giant LVMH. This follows the UK launch of Wegovy, a weight loss drug that cuts appetite and cravings. Tens of thousands of people have already signed up to waiting lists for the treatment. Also…

Launch of weight-loss drug in UK helps Danish firm to market value of $428bn

Ministers have announced plans which could see tens of thousands given access to new weight-loss drug